Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)
Phase 1
Completed
- Conditions
- Healthy Postmenopausal Females
- Interventions
- Drug: Commercial NOMAC-E2Drug: Phase 3 NOMAC-E2 "Batch A"Drug: Phase 3 NOMAC-E2 "Batch B"
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 158
- Registration Number
- NCT01345786
A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)
Not Applicable
Completed
- Conditions
- DyslipidemiaHypercholesterolemia
- Interventions
- Other: Test Meal
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 93
- Registration Number
- NCT01333436
- Locations
- 🇰🇷
MSD Korea Ltd., Seoul, Korea, Republic of
Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)
Completed
- Conditions
- Spondylarthropathies; Spondylitis, Ankylosing
- Interventions
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 21108
- Registration Number
- NCT01327638
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 278
- Registration Number
- NCT01307033
MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Placebo to MK-0954A
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 336
- Registration Number
- NCT01307046
Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 711
- Registration Number
- NCT01304511
Survey of Osteoarthritis Real World Therapies (MK-0663-140)
Completed
- Conditions
- Osteoarthritis
- Interventions
- Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s)
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1261
- Registration Number
- NCT01294696
Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1959
- Registration Number
- NCT01286207
Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Placebo to match losartan/amlodipine tabletsDrug: Placebo to match amlodipine
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 334
- Registration Number
- NCT01277822
A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: ENG 120 µg + EE 15 µg intravaginal ring
- First Posted Date
- 2011-01-14
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 983
- Registration Number
- NCT01277211